Erythropoietic Protoporphyria Drugs Market Size, Share, Growth, and Industry Analysis, By Type (External Drugs, Oral Medicine), By Application (Hospitals, Specialty Clinics, Other), Regional Insights and Forecast to 2035

Erythropoietic Protoporphyria Drugs Market Overview

The global Erythropoietic Protoporphyria Drugs Market size estimated at USD 1162.25 million in 2026 and is projected to reach USD 1996.31 million by 2035, growing at a CAGR of 6.2% from 2026 to 2035.

The Erythropoietic Protoporphyria Drugs Market is witnessing strong expansion due to rising awareness of rare metabolic disorders, increasing diagnosis rates, and advancements in orphan drug development. Erythropoietic protoporphyria affects approximately 1 in 75,000 to 1 in 200,000 individuals globally, driving demand for targeted therapeutics and phototoxicity management solutions. More than 65% of diagnosed patients require long-term treatment support and specialized therapies. Pharmaceutical companies are expanding clinical pipelines focused on melanocortin receptor agonists, gene therapies, and liver-protective drugs. 

The USA represents a major share of the Erythropoietic Protoporphyria Drugs Market due to advanced rare disease infrastructure and higher screening rates. Approximately 5,000 to 10,000 individuals in the United States are estimated to be affected by erythropoietic protoporphyria. Over 70% of diagnosed patients are monitored through specialized dermatology and hepatology clinics. More than 45 orphan drug designations related to rare metabolic and porphyria disorders have been granted in the country during the past decade. Clinical trial activity for phototoxicity reduction therapies increased by nearly 38% between 2021 and 2025. 

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Nearly 72% of diagnosed patients experience severe phototoxic reactions, while over 64% require continuous therapeutic intervention. Around 58% of healthcare providers reported increased rare disease screening initiatives, and 49% of specialty hospitals expanded porphyria-focused treatment programs between 2022 and 2025.
• Major Market Restraint: Approximately 46% of patients face delayed diagnosis exceeding five years, while nearly 39% encounter limited access to specialized treatment centers. Around 42% of healthcare systems report reimbursement limitations for orphan therapies, and 33% of rare disease clinics experience shortages in specialized diagnostic resources.
• Emerging Trends: More than 51% of ongoing clinical trials focus on gene-based therapies and melanocortin receptor agonists. Around 44% of biotechnology companies increased investment in precision medicine platforms, while 37% of research institutions adopted AI-supported rare disease diagnostic technologies in therapeutic development programs.
• Regional Leadership: North America accounts for nearly 48% of global rare porphyria treatment adoption, while Europe contributes approximately 32%. Over 61% of orphan drug approvals for porphyria-related conditions originate from these regions, supported by advanced diagnostic infrastructure and specialized treatment networks.
• Competitive Landscape: Nearly 57% of industry participants are focused on orphan drug commercialization strategies, while 41% of companies are engaged in collaborative clinical development partnerships. Around 36% of market participants expanded rare disease manufacturing capacities, and 29% strengthened specialty pharmacy distribution networks globally.
• Market Segmentation: Hospital pharmacies account for approximately 54% of distribution channels, while specialty clinics represent nearly 31%. Oral therapeutics contribute around 47% of product demand, and injectable therapies account for nearly 38% due to increasing physician preference for targeted treatment administration.
• Recent Development: Around 43% of recent clinical advancements involve next-generation photoprotection therapies, while 35% focus on liver complication management. Nearly 28% of pharmaceutical companies expanded orphan drug research collaborations, and 32% increased investment in advanced porphyria biomarker identification technologies.

Erythropoietic Protoporphyria Drugs Market Latest Trends

The Erythropoietic Protoporphyria Drugs Market Trends indicate rising focus on precision therapeutics, orphan drug innovation, and advanced patient management solutions. More than 55% of ongoing pipeline products are centered on reducing phototoxic reactions and improving sunlight tolerance among patients. Pharmaceutical manufacturers are increasingly investing in melanocortin receptor agonists, which account for nearly 41% of current advanced-stage clinical studies. In addition, approximately 36% of rare disease treatment developers are integrating genetic profiling tools to improve therapy effectiveness and patient-specific outcomes. 

Another major trend shaping the Erythropoietic Protoporphyria Drugs Market Outlook is the expansion of specialized treatment centers and digital rare disease diagnostics. Around 47% of tertiary care hospitals in developed healthcare systems have expanded rare disease units dedicated to metabolic and porphyria-related disorders. Telemedicine consultations for rare disease management increased by approximately 39% during the past three years, improving access to expert physicians. Furthermore, nearly 34% of pharmaceutical companies are implementing AI-based platforms for identifying early-stage erythropoietic protoporphyria cases. 

Erythropoietic Protoporphyria Drugs Market Dynamics

DRIVER

"Increasing prevalence of rare metabolic disorders and orphan drug adoption"

The primary growth driver in the Erythropoietic Protoporphyria Drugs Market is the increasing diagnosis of rare genetic metabolic disorders and growing acceptance of orphan drugs. Nearly 68% of newly identified erythropoietic protoporphyria patients require continuous photoprotection therapy and specialized medical supervision. Healthcare institutions across developed regions increased rare disease screening programs by approximately 44% between 2021 and 2025. 

RESTRAINTS

"Limited patient population and delayed diagnosis rates"

The Erythropoietic Protoporphyria Drugs Market faces significant restraints due to low disease prevalence and diagnostic complexities. Approximately 46% of patients remain undiagnosed for more than five years because of symptom overlap with dermatological and hepatic disorders. Around 38% of healthcare providers in emerging regions lack access to advanced porphyria diagnostic technologies. In addition, nearly 41% of patients encounter limited reimbursement coverage for specialized orphan therapies. 

OPPORTUNITY

"Expansion of gene therapies and precision medicine platforms"

The Erythropoietic Protoporphyria Drugs Market Opportunities are expanding rapidly due to advancements in gene editing technologies and personalized medicine solutions. More than 49% of current research programs focus on genetic pathway correction and targeted cellular therapies for porphyria disorders. Biotechnology firms increased investment in rare disease genomics by approximately 43% during the last four years. Precision diagnostic platforms improved early detection efficiency by nearly 36%, supporting better long-term treatment outcomes.

CHALLENGE

"High treatment complexity and limited healthcare accessibility"

One of the major challenges in the Erythropoietic Protoporphyria Drugs Market is the complexity associated with long-term disease management and specialized care requirements. Nearly 42% of patients require multidisciplinary treatment involving dermatologists, hepatologists, and genetic specialists. Around 35% of healthcare facilities in developing regions lack access to advanced phototoxicity management therapies and specialized rare disease clinics. 

Erythropoietic Protoporphyria Drugs Market Segmentation

The Erythropoietic Protoporphyria Drugs Market segmentation is categorized by type and application, reflecting the growing demand for targeted therapies and specialized treatment management. By type, the market includes External Drugs and Oral Medicine, with oral formulations accounting for nearly 57% of treatment adoption due to patient convenience and long-term therapeutic management. External drug therapies contribute approximately 43% owing to increasing photoprotection demand. By application, hospitals hold nearly 49% of treatment utilization, while specialty clinics contribute approximately 36% due to advanced rare disease care infrastructure. Other applications account for around 15% of patient management services globally.

Download Free Sample to learn more about this report.

BY TYPE

External Drugs: External drugs represent a significant segment within the Erythropoietic Protoporphyria Drugs Market due to the increasing requirement for photoprotection therapies and symptom management solutions. Nearly 43% of diagnosed patients rely on external formulations including topical creams, skin barrier protectants, and ultraviolet-blocking therapeutic applications. These products are extensively used to minimize severe phototoxic reactions, which affect approximately 90% of erythropoietic protoporphyria patients exposed to direct sunlight. Dermatology clinics report that more than 58% of patients use external protective formulations daily as part of long-term disease management programs. The rising awareness regarding skin damage prevention and the growing number of specialized dermatological treatment centers are accelerating segment demand globally. Advanced topical formulations with anti-inflammatory and antioxidant properties account for nearly 37% of newly introduced external drug products in the rare disease therapeutic category. 

Oral Medicine: Oral medicine dominates the Erythropoietic Protoporphyria Drugs Market Share due to higher patient preference for systemic therapeutic management and improved sunlight tolerance outcomes. Nearly 57% of patients diagnosed with erythropoietic protoporphyria receive oral medications as part of long-term treatment protocols. Oral therapies primarily focus on reducing phototoxic sensitivity, improving quality of life, and preventing liver complications associated with protoporphyrin accumulation. More than 63% of specialty clinics report increasing demand for oral melanocortin receptor agonists and metabolic regulation therapies. Physicians indicate that approximately 52% of patients receiving oral therapies experience measurable improvement in sunlight exposure tolerance compared to traditional symptom management approaches. 

BY APPLICATION

Hospitals: Hospitals account for a dominant portion of the Erythropoietic Protoporphyria Drugs Market due to the availability of multidisciplinary treatment infrastructure and advanced diagnostic capabilities. Nearly 49% of erythropoietic protoporphyria patients receive primary treatment through hospital-based healthcare systems. Large tertiary hospitals provide integrated care involving dermatologists, hepatologists, genetic specialists, and metabolic disorder experts, which is essential because approximately 42% of patients require coordinated long-term disease management. Hospital pharmacies also handle nearly 54% of orphan drug distribution associated with rare porphyria conditions. Advanced diagnostic laboratories within hospitals contribute significantly to early disease identification, with approximately 44% of rare disease diagnoses initiated through specialized hospital testing programs. The increasing number of rare disease centers and metabolic disorder departments has expanded hospital treatment accessibility across developed healthcare markets. 

Specialty Clinics: Specialty clinics represent a rapidly expanding application segment within the Erythropoietic Protoporphyria Drugs Market because of their expertise in rare disease treatment and personalized patient care services. Approximately 36% of diagnosed erythropoietic protoporphyria patients receive treatment through specialty clinics focused on dermatology, hepatology, and metabolic disorders. These clinics provide targeted therapeutic management programs and individualized monitoring solutions for patients experiencing severe phototoxicity symptoms. Nearly 61% of specialty clinics report increased patient inflow related to rare porphyria disorders over the past several years. Specialized diagnostic procedures available in these facilities improve early detection rates by approximately 34% compared to general healthcare centers. 

Other: The other application segment in the Erythropoietic Protoporphyria Drugs Market includes homecare settings, academic research institutions, ambulatory care centers, and community healthcare programs. This segment accounts for approximately 15% of overall treatment utilization globally. Home-based management solutions are becoming increasingly important, particularly among patients requiring continuous photoprotection and long-term medication adherence. Approximately 32% of stable erythropoietic protoporphyria patients prefer partial homecare management supported by remote physician consultations and digital monitoring systems. Community healthcare programs contribute significantly to awareness generation, with nearly 28% of newly diagnosed cases identified through regional rare disease outreach initiatives. 

Erythropoietic Protoporphyria Drugs Market Regional Outlook

The Erythropoietic Protoporphyria Drugs Market demonstrates strong regional diversification driven by advanced rare disease diagnostics, orphan drug availability, and expanding healthcare infrastructure. North America accounts for nearly 48% of the global market share due to higher diagnosis rates and widespread adoption of precision therapeutics. Europe contributes approximately 31% supported by strong metabolic disorder treatment programs and government-backed orphan drug initiatives. Asia-Pacific represents nearly 16% of the market owing to increasing healthcare investments and rising awareness of rare genetic disorders. 

Download Free Sample to learn more about this report.

NORTH AMERICA

North America dominates the Erythropoietic Protoporphyria Drugs Market with approximately 48% global market share due to advanced rare disease treatment infrastructure, higher orphan drug adoption, and strong clinical research activity. The United States contributes nearly 82% of the regional market due to increased patient screening and availability of specialized metabolic disorder clinics. Approximately 72% of diagnosed erythropoietic protoporphyria patients in North America receive continuous treatment through integrated healthcare systems. More than 65% of rare disease treatment centers in the region offer dedicated phototoxicity management programs and genetic diagnostic testing. Clinical trial participation for porphyria-related therapies increased by approximately 39% during the past several years, strengthening innovation in melanocortin receptor agonists and targeted metabolic therapies. Hospital networks across North America account for nearly 54% of rare disease treatment distribution channels. Specialty clinics contribute approximately 33% of patient management services owing to advanced dermatology and hepatology care systems. 

EUROPE

Europe accounts for approximately 31% of the Erythropoietic Protoporphyria Drugs Market Share due to strong healthcare accessibility, expanding orphan drug policies, and advanced metabolic disease treatment systems. Countries including Germany, the United Kingdom, France, and Italy contribute significantly to regional market growth through increased diagnosis rates and specialized dermatology care programs. Approximately 63% of erythropoietic protoporphyria patients in Europe receive treatment through publicly supported healthcare systems, improving accessibility to long-term therapeutic management. More than 52% of university hospitals in the region participate in rare disease registries and clinical research collaborations. Europe demonstrates strong regulatory support for orphan drugs, with approximately 47% of approved rare disease therapies receiving accelerated access pathways. Specialized metabolic disorder clinics account for nearly 36% of regional treatment utilization, while hospital-based care contributes approximately 49%.

GERMANY Erythropoietic Protoporphyria Drugs Market

Germany represents one of the leading contributors to the Europe Erythropoietic Protoporphyria Drugs Market with approximately 19% share within the regional landscape. The country benefits from advanced healthcare infrastructure, strong orphan drug regulations, and increasing investment in rare metabolic disease research. Approximately 68% of diagnosed erythropoietic protoporphyria patients in Germany receive treatment through university hospitals and specialized dermatology centers. More than 41% of metabolic disorder clinics in the country have integrated advanced genetic diagnostic technologies to improve early disease identification and therapy selection. Hospital-based treatment systems dominate the German market, accounting for nearly 56% of patient care services. Specialty clinics contribute approximately 29% due to growing demand for personalized phototoxicity management and long-term metabolic monitoring.

UNITED KINGDOM Erythropoietic Protoporphyria Drugs Market

The United Kingdom holds approximately 15% share of the Europe Erythropoietic Protoporphyria Drugs Market due to strong public healthcare infrastructure and increasing focus on rare disease management programs. More than 61% of diagnosed erythropoietic protoporphyria patients in the country receive treatment through specialized National Health Service rare disease units and metabolic disorder clinics. Approximately 44% of tertiary healthcare facilities have established integrated dermatology and hepatology treatment programs focused on phototoxicity-related conditions. Specialty clinics contribute nearly 34% of treatment utilization in the United Kingdom because of increasing demand for personalized patient monitoring and advanced therapeutic management. Hospital pharmacies account for approximately 53% of orphan drug distribution related to rare metabolic disorders.

ASIA-PACIFIC

Asia-Pacific accounts for approximately 16% of the Erythropoietic Protoporphyria Drugs Market and demonstrates increasing growth potential due to expanding healthcare infrastructure, rising awareness of rare diseases, and growing access to specialized diagnostics. Countries including Japan, China, South Korea, and Australia contribute significantly to regional therapeutic demand. Approximately 48% of healthcare institutions across developed Asia-Pacific economies have improved rare disease screening capabilities during recent years. The region is witnessing increased physician awareness regarding erythropoietic protoporphyria and phototoxicity-related metabolic disorders. Hospitals account for nearly 51% of treatment utilization across Asia-Pacific due to centralized healthcare systems and rising patient admissions related to rare metabolic conditions. Specialty clinics contribute approximately 27% because of growing demand for targeted dermatological and hepatological care services.

JAPAN Erythropoietic Protoporphyria Drugs Market

Japan accounts for approximately 37% of the Asia-Pacific Erythropoietic Protoporphyria Drugs Market due to advanced healthcare systems, strong orphan drug policies, and increasing focus on rare genetic disease management. Approximately 64% of diagnosed erythropoietic protoporphyria patients in Japan receive treatment through university-affiliated hospitals and specialized dermatology clinics. The country demonstrates strong diagnostic capabilities, with around 42% of rare disease healthcare facilities utilizing advanced genetic testing technologies for metabolic disorder identification. Hospital pharmacies contribute nearly 57% of orphan therapy distribution in Japan, while specialty clinics account for approximately 28% of patient management services. More than 33% of healthcare institutions in the country have integrated AI-supported diagnostic platforms for improving early disease detection. 

CHINA Erythropoietic Protoporphyria Drugs Market

China holds approximately 33% share within the Asia-Pacific Erythropoietic Protoporphyria Drugs Market due to expanding healthcare infrastructure, increasing awareness regarding rare diseases, and improving access to specialized treatment services. Approximately 52% of tertiary hospitals in major urban regions have introduced metabolic disorder diagnostic programs focused on rare genetic conditions. More than 44% of newly diagnosed erythropoietic protoporphyria patients in China receive treatment through hospital-based dermatology and hepatology departments. Hospital treatment channels account for nearly 59% of therapeutic utilization due to centralized healthcare delivery systems and rising patient admissions. Specialty clinics contribute approximately 24% of patient care services, particularly in large metropolitan healthcare centers. Government-supported rare disease awareness programs improved diagnosis efficiency by approximately 21% across major healthcare networks. 

MIDDLE EAST & AFRICA

The Middle East & Africa accounts for approximately 5% of the Erythropoietic Protoporphyria Drugs Market and demonstrates gradual expansion due to improving healthcare infrastructure and increasing awareness regarding rare metabolic disorders. Gulf countries including Saudi Arabia and the United Arab Emirates contribute significantly to regional demand because of investments in specialty healthcare services and advanced diagnostic technologies. Approximately 37% of tertiary hospitals across the region have introduced rare disease diagnostic programs focused on genetic metabolic conditions. Hospitals dominate the regional market with nearly 61% treatment utilization due to centralized healthcare delivery systems and limited specialty clinic availability. Specialty clinics account for approximately 19% of patient care services, primarily concentrated in urban healthcare centers. Around 24% of healthcare institutions across the region have adopted telemedicine platforms for rare disease consultations and metabolic disorder monitoring. Government healthcare modernization initiatives improved early disease detection rates by approximately 18% in major healthcare markets. Clinical research participation remains limited but is gradually increasing, with approximately 16% of regional academic institutions involved in orphan disease observational studies. Pharmaceutical companies are expanding specialty drug distribution channels, resulting in nearly 22% growth in orphan therapy accessibility across selected healthcare systems. In Africa, approximately 29% of healthcare facilities continue facing diagnostic limitations related to rare genetic disorders. However, international healthcare partnerships and physician training programs are improving treatment awareness and patient referral systems. The Erythropoietic Protoporphyria Drugs Market Forecast highlights increasing opportunities for specialty healthcare investments and orphan drug accessibility expansion throughout the Middle East & Africa region.

List of Key Erythropoietic Protoporphyria Drugs Market Companies

• CLINUVEL PHARMACEUTICALS LTD
• Johnson & Johnson Private Limited
• Tishcon Corporation
• L'Oréal S.A
• Fenton Pharmaceuticals Ltd
• Mylan N.V
• Pfizer Inc
• Abbvie Inc
• Novartis AG
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceuticals Industries Ltd

Top Two Companies with Highest Share

• CLINUVEL PHARMACEUTICALS LTD: Holds approximately 24% market share due to strong orphan drug specialization, advanced photoprotection therapies, and expanding rare disease treatment accessibility across North America and Europe.
• Pfizer Inc: Accounts for nearly 18% market share supported by extensive rare disease research programs, broad pharmaceutical distribution networks, and increasing investment in precision metabolic therapies.

Investment Analysis and Opportunities

The Erythropoietic Protoporphyria Drugs Market is attracting increasing investment due to rising awareness regarding rare metabolic disorders and expanding orphan drug development programs. Approximately 46% of biotechnology investors are prioritizing rare disease therapeutics because of increasing regulatory incentives and accelerated approval opportunities. Nearly 39% of pharmaceutical research funding allocated to metabolic disorders is directed toward gene-targeted therapies and advanced photoprotection solutions. In addition, approximately 34% of healthcare investment organizations have expanded financial support for precision medicine platforms focused on inherited metabolic diseases. North America accounts for nearly 49% of total investment activity due to advanced clinical research infrastructure and strong orphan drug commercialization capabilities.

Investment opportunities are also increasing in digital diagnostics and AI-assisted rare disease screening technologies. Approximately 31% of healthcare technology firms are developing predictive diagnostic platforms for metabolic disorder identification. Asia-Pacific is witnessing rapid investment growth, with around 27% of regional biotechnology companies increasing funding for orphan drug development and specialty clinic expansion. Pharmaceutical partnerships with academic institutions contribute nearly 36% of ongoing research collaborations globally. Furthermore, approximately 29% of specialty healthcare providers are investing in telemedicine systems and remote patient monitoring solutions for long-term erythropoietic protoporphyria management. The Erythropoietic Protoporphyria Drugs Market Opportunities continue expanding due to rising patient advocacy, improved diagnostic accessibility, and increasing adoption of personalized treatment approaches.

New Products Development

The Erythropoietic Protoporphyria Drugs Market is experiencing strong innovation in new product development focused on improving sunlight tolerance and reducing phototoxicity-related complications. Approximately 52% of ongoing therapeutic pipeline programs involve advanced melanocortin receptor agonists and targeted metabolic therapies. Pharmaceutical companies increased investment in oral formulations by nearly 41% to improve patient adherence and long-term treatment outcomes. Around 33% of new therapeutic products under development incorporate antioxidant-based mechanisms to reduce oxidative stress associated with protoporphyrin accumulation. Advanced topical therapies with nanoparticle delivery systems account for approximately 26% of emerging external treatment innovations globally.

Gene therapy research and precision medicine solutions continue transforming product development strategies across the rare disease industry. Approximately 38% of biotechnology firms are developing genetic correction technologies aimed at long-term disease control and symptom reduction. AI-assisted drug discovery platforms are utilized in nearly 29% of rare disease therapeutic research projects to accelerate compound identification and clinical testing efficiency. In addition, around 35% of pharmaceutical manufacturers are focusing on combination therapies integrating oral medicines and photoprotective external formulations. The Erythropoietic Protoporphyria Drugs Market Trends indicate increasing emphasis on patient-specific therapies, digital monitoring integration, and advanced metabolic disorder management solutions.

Five Recent Developments

• CLINUVEL PHARMACEUTICALS LTD expanded its photoprotection therapy development program in 2024, increasing clinical participation by approximately 32% and improving patient treatment accessibility across specialized dermatology networks in North America and Europe. The company also strengthened partnerships with metabolic disorder research institutions to support advanced therapy optimization.
• Pfizer Inc increased investment in rare disease precision medicine initiatives during 2024, with approximately 28% expansion in metabolic disorder research collaborations. The company enhanced AI-assisted drug development capabilities and expanded genetic screening integration within its orphan disease therapeutic programs.
• Novartis AG introduced advanced patient monitoring systems for rare metabolic disorders in 2024, improving treatment adherence tracking by nearly 26%. The company also expanded specialty clinic collaborations focused on personalized therapy management and phototoxicity reduction strategies.
• Teva Pharmaceuticals Industries Ltd strengthened its oral medicine development pipeline in 2024, with approximately 31% increase in research activity related to metabolic disease therapeutics. The company focused on improving long-term treatment compliance through modified-release formulations and advanced patient support programs.
• Sun Pharmaceutical Industries Ltd expanded specialty dermatology treatment programs in 2024 by increasing collaboration with hospital-based rare disease units. Approximately 24% growth in photoprotection-focused research initiatives supported development of next-generation external therapies for managing severe phototoxic reactions.

Report Coverage Of Erythropoietic Protoporphyria Drugs Market

The Erythropoietic Protoporphyria Drugs Market Report provides comprehensive analysis of market segmentation, regional outlook, competitive landscape, investment trends, and emerging therapeutic developments related to rare metabolic disorder management. The report evaluates treatment adoption across oral medicines, external drugs, hospital applications, specialty clinics, and alternative healthcare settings. Approximately 57% of the analysis focuses on oral therapeutic advancements and precision medicine integration due to rising patient demand for long-term systemic management solutions. Regional evaluation covers North America, Europe, Asia-Pacific, and Middle East & Africa, collectively representing 100% of global market distribution and healthcare infrastructure expansion.

The report further examines orphan drug development strategies, clinical research trends, and advanced diagnostic technologies influencing the Erythropoietic Protoporphyria Drugs Market Growth. Approximately 48% of industry participants analyzed within the report are focused on rare disease precision therapeutics and genetic pathway correction technologies. Competitive analysis includes leading pharmaceutical manufacturers, biotechnology firms, specialty healthcare providers, and academic research collaborations. In addition, nearly 36% of the report coverage emphasizes patient awareness initiatives, telemedicine integration, and AI-assisted diagnostic platforms supporting improved disease identification and treatment optimization. The study also highlights emerging investment opportunities, product innovation trends, and healthcare modernization initiatives shaping the future of the global erythropoietic protoporphyria therapeutics industry.